Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid

British Journal of Cancer

Volumn 80, Issue 5-6, 1999, Pages 716-723

  Cao, Z ^a   Joseph, W R ^a   Browne, W L ^a   Mountjoy, K G ^b   Palmer, B D ^a   Baguley, B C ^a   Ching, L M ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Colon 38; DMXAA; Endotoxin; Thalidomide; Tumour necrosis factor

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANTINEOPLASTIC AGENT; LIPOPOLYSACCHARIDE; MESSENGER RNA; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG STRUCTURE; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TISSUE LEVEL; TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLONIC NEOPLASMS; DRUG SYNERGISM; FEMALE; LIPOPOLYSACCHARIDES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NEOPLASM TRANSPLANTATION; RNA, MESSENGER; SPLEEN; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0032895102     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690415     Document Type: Article

References (42)

1. Browne WL, Wilson WR, Rutland M, Baguley BC and Ching L-M (1998) Suppression of serum tumor necrosis factor-α by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5.6-dimethylxanthenone-4 acetic acid. Anticancer Res 18: 4409-4414
2. Burroughs MH, Tsenova-Berkova L, Sokol K, Ossig J, Tuomanen E and Kaplan G (1995) Effect of thalidomide on the inflammatory response in cerebrospinal fluid in experimental bacterial meningitis. Microb Pathogen 19: 245-255
3. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P and Calvieri S (1995) Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol 32: 866-869
4. Casini G and Ferappi M (1964) Preparation of one optical antipode of 2-phthalimidoglutarimide. Farmaco 19: 563-565
5. Ching LM, Joseph WR, Zhuang L, Atwell GJ, Rewcastle GR, Denny WA and Baguley BC (1991) Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with anti-tumour activity. Eur J Cancer 27: 79-83
6. Ching LM, Joseph WR and Baguley BC (1992) Anti-tumour responses to flavone-8 acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128-130
7. Ching LM, Joseph WR, Crosier KE and Baguley BC (1994a) Induction of tumour necrosis factor alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54: 870-872
8. Ching LM, Joseph WR, Zhuang L and Baguley BC (1994b) Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhage necrosis of Colon 38 tumours. Cancer Chemother Pharmacol 35: 153-160
9. Ching LM, Xu Z-F, Gummer BH, Palmer BD, Joseph WR and Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 72: 339-343
10. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC and Palmer BD (1998) Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of antitumour activity. Br J Cancer 78: 336-343
11. D'Amato RJ, Loughnan MS, Flynn E and Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085
12. Fabro S, Smith RL and Williams RT (1967) Toxicity and teratogenicity of optical isomers of thalidomide. Nature 215: 296
13. Gardner-Medwin JM, Smith NJ and Powell RJ (1994) Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 53: 828-832
14. Gutierrez-Rodriguez O, Starusta-Bacal P and Gutierrez-Montes O (1989) Treatment of refractory rheumatoid arthritis: the thalidomide experience. J Rheumatol 16: 158-163
15. Han J, Thompson P and Beutler B (1990) Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 172: 391-394
16. Haslett PAJ, Corral LG, Albert M and Kaplan G (1998) Thalidomide costimulates primary human 1 lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the cd8+ subset. J Exp Med 187: 1885-1892
17. Hogan MM and Vogel SN (1990) Measurement of tumor necrosis factor alpha and beta. In Current Protocols in Immunology, Vol. I, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM and Strober W (eds), p. 6,10,1. Greene Publishing Associates and Wiley Interscience: New York
18. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC and Ching LM (1999) Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633-638
19. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ and Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanethenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78: 439-445
20. Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP and Hart IR (1990) Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 50: 5537-5542
21. Makonkawkeyoon S, Limson-Pobre RNR, Moreira AL, Schauf V and Kaplan G (1993) Thalidomide inhibits the replication of human immunodeficiency virus type I. Proc Natl Acad Sci USA 90: 5974-5978
22. Miyachi H, Azuma A, Hioki E, Iwasaki S, Kobayashi Y and Hashimoto Y (1996) Inducer-specific bidirectional regulation by thalidomide and phenylphthalimides of tumor necrosis factor-alpha production. Biochem Biophys Res Commun 224: 426-430
23. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA and Kaplan G (1993) Thalidomide exerts its inhibitory action on tumour necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177: 1675-1680
24. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, Freedman VH and Kaplan G (1997) Thalidomide and thalidomide analogs reduce HIV type I replication in human macrophages in vitro. AIDS Res Hum Retroviruses 13: 857-863
25. Patel S, Parkin SM and Bibby MC (1997) The effect of 5,6-dimethylxanthenone 4-acetic acid on tumor necrosis factor production hy human immune cells. Anticancer Res 17: 141-150
26. Philpott M, Baguley BC and Chung L-M (1995) Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 36: 143-148
27. Philpott M, Joseph WR, Crosier KE, Baguley BC and Ching LM (1997) Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Br J Cancer 76: 1586-1591
28. Pratesi G, Rodolfo M, Rovetta G and Parmiani G (1990) Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 26: 1079-1083
29. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC and Denny WA (1991) Potential antitumor agents, 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34: 217-222
30. Sampaio EP, Sarno EN, Galilly R, Cohn ZA and Kaplan G (1991) Thalidomide selectively inhibits tumor necrosis factor-alpha production by stimulated human monocytes. J Exp Med 173: 699-703.
31. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA and Jongeneel CV (1990) Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171: 35-47
32. Shannon EJ and Sandoval F (1996) Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells. Immunopharmacol Immunotoxicol 18: 59-72
33. Shannon EJ, Howe RC, McLean K and Hastings RC (1994) Thalidomide does not perturb CD2, CD4, CD5, CD8, HLA-DR, or HLA-A, B, C molecules in vitro on the membranes of cells with immune potential. Immunopharmacol Immunotoxicol 16: 717-729
34. Sheskin J (1965) Further observation with thalidomide in lepra reactions. Leprosy Res 36: 183-187
35. Silva SRB, Viana PCf, Lugon NV, Hoette M, Ruzany F and Lugon JR (1994) Thalidomide for the treatment of uremic pruritus: a crossover randomised double-blind trial. Life Sci 31: 270-273
36. Teicher BA, Sotomayor EA and Huang ZD (1992) Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704
37. Turk BE, Jiang H and Liu JO (1996) Binding of thalidomide to alpha(1)-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci USA 93: 7552-7556
38. Uthoff K, Zehr KJ, Gaudin PB, Kumar P, Cho PW, Vogelsang G, Hruban RH, Baumgartner WA and Stuart RS (1995) Thalidomide as replacement for steroids in immunosuppression after lung transplantation. Ann Thorax Surg 59: 277-282
39. Vogelsang GB, Santos GW, Colvin OM and Chen T (1988) Thalidomide for graft verus-host disease. Lancet 1: 827
40. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR and Santos GW (1992) Thalidomide for the treatment of chronic graft-versus-host disease. New England J Med 326: 1055-1058
41. Yang D, Satoh M, Ueda H, Tsukagoshi S and Yamazaki M (1994) Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38: 287-293
42. Zwi LJ, Baguley BC, Gavin JB and Wilson WR (1994) Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 6: 79-85